Close Menu

NEW YORK – Molecular diagnostic reagent developer BioGX and Bosch Healthcare Solutions, a subsidiary of the Bosch Group, announced Wednesday a partnership to develop point-of-care infectious disease tests for Bosch's Vivalytic platform.

Birmingham, Alabama-based BioGX will develop, manufacture, and supply reagents for the Vivalytic cartridges, along with providing custom reagent manufacturing services for Vivalytic open system users. The companies said they will work together to seek regulatory approvals in different countries for in vitro diagnostic use.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.